ライフサイエンスコーパス: serum glucose

1 after adjustment for diabetes treatment and serum glucose.

2 nsgene reverses the effect of CC ablation on serum glucose.

3 glucose infusion rates to maintain a similar serum glucose.

4 n approach used here in the determination of serum glucose.

5 cholesterols, triglycerides and decrease the serum glucose.

6 liver masses, hepatic fat accumulation, and serum glucose.

7 using information on hypoglycemic agents and serum glucose.

8 levels, and lowers hepatic triglycerides and serum glucose.

9 also significantly related to higher fasting serum glucose.

10 ression of gluconeogenic genes and decreased serum glucose.

11 tively randomized to tight glycemic control (serum glucose, 125 to 200 mg/dL) with GIK or standard th

12 , with reduced leptin (20-fold) and elevated serum glucose (3-fold), insulin (50- to 400-fold), free

13 compared with control mice had lower fasting serum glucose (4.8 +/- 0.5 mmol/l in transgenic mice vs.

14 stration to ob/ob mice also markedly reduced serum glucose (8.3 +/- 1.2 vs. 24.5 +/- 3.8 mmol/l; P <

15 Average daily serum glucose, admission serum albumin, time to initiati

16 ine ingestion results in a small decrease in serum glucose and an increase in glucagon and insulin co

17 DL-cholesterols, triglycerides and increased serum glucose and body weight of the animals.

18 ) mice, associated with similar increases in serum glucose and cholesterol.

19 Serum glucose and cholesterol/triglycerides in the liver

20 At 1 year after transplant, the mean serum glucose and creatinine levels were not different b

21 Core temperature, hemodynamics, serum glucose and electrolytes, and P/F were sequentiall

22 to the action of insulin and in normalizing serum glucose and free fatty acids in type 2 diabetic pa

23 s in subgingival plaque and determination of serum glucose and glycated hemoglobin (HbA1c).

24 s classified based on self-report or fasting serum glucose and glycated hemoglobin levels.

25 ocin-treated mice showed increased levels of serum glucose and growth retardation consistent with a s

26 Serum glucose and hepatic steatosis was significantly re

27 Ozone-exposed dams also had lower serum glucose and higher free fatty acid concentrations

28 ing FFAs, which was associated with elevated serum glucose and impaired glucose and insulin tolerance

29 a in Acox1-deficient ob/ob mice also reduces serum glucose and insulin (P<0.05) and improves glucose

30 s of the WHI low-fat dietary intervention on serum glucose and insulin and insulin resistance up to 6

31 iabetes and higher concentrations of fasting serum glucose and insulin are associated with increased

32 The pinitol-enriched beverage reduced serum glucose and insulin at 45 and 60min, but only at a

33 nthropometric measures, dietary assessments, serum glucose and insulin concentrations, homeostasis mo

34 ose of caloric restriction including reduced serum glucose and insulin levels and increased resistanc

35 Fasting serum glucose and insulin levels were measured at 7-day

36 ght gain, with normal maintenance of fasting serum glucose and insulin levels.

37 Serum glucose and insulin samples were measured at basel

38 Serum glucose and insulin were monitored for 5 h posting

39 Levels of serum glucose and insulin were significantly decreased i

40 e physiological impact of different foods on serum glucose and insulin, and such information should r

41 d not result in obesity but led to increased serum glucose and insulin, reduced muscle glucose uptake

42 thermogenesis, weight loss and reduction in serum glucose and lipid levels.

43 ared with 33 and 71% who had measurements of serum glucose and lipids, respectively.

44 the partial protection against the elevated serum glucose and obesity seen in type 2 diabetes-like m

45 The association between serum glucose and odds of TOF indicates the need for add

46 in mice, which is associated with decreased serum glucose and triacylglycerol levels.

47 cy, fetal growth restriction, elevated fetal serum glucose and triglyceride levels.

48 lture under stress conditions (withdrawal of serum/glucose and/or antioxidants), OPCs showed increase

49 icant adverse effect on serum lipid, fasting serum glucose, and fasting serum insulin levels, or bloo

50 luded height, weight, blood pressure, random serum glucose, and glycosylated hemoglobin measurements.

51 d profile, cotinine-assessed smoke exposure, serum glucose, and questionnaire data on socioeconomic a

52 ions, and atrial fibrillation), the level of serum glucose, and the incidence of hypoglycemic events.

53 The mean 24-h integrated serum glucose at the end of the control and LoBAG diets

54 titutes of Health Stroke Scale score, higher serum glucose, atrial fibrillation, and any impairment i

55 Serum glucose (average value and maximum value each day)

56 ing for donor age, body mass index, baseline serum glucose, baseline serum cholesterol, recipient age

57 of insects such as Drosophila also regulate serum glucose, but it remains unclear whether insulin is

58 Mean serum glucose, cholesterol, and triglyceride levels were

59 p diabesity, with no improvements in fasting serum glucose, cholesterol, weight, body composition, or

60 t interaction of the observed relations with serum glucose concentration (P < 0.05).

61 If validated prospectively, serum glucose concentration alone might be an indicator

62 A high-serum glucose concentration alters intraglomerular hemod

63 Diabetic rats had a mean serum glucose concentration of 490 mg/dl and consumed eq

64 lished vs. newly diagnosed disease), initial serum glucose concentration, and initial venous pH.

65 hat may, in part, explain the observed lower serum glucose concentration.

66 H-linked substrates and these rats had lower serum glucose concentration.

67 he increase in activity was in proportion to serum glucose concentration.

68 lding capacity, is still capable of reducing serum glucose concentrations and increasing glucose tole

69 High serum glucose concentrations are known to induce the pol

70 Serum glucose concentrations correlate directly with the

71 up given 600 mg of troglitazone, and fasting serum glucose concentrations decreased by 35 and 49 mg p

72 The median peak serum glucose concentrations for these two groups were 3

73 retion resulted in a transient correction of serum glucose concentrations in a mouse model of hypergl

74 7.9% (2.3); 51% of patients had preoperative serum glucose concentrations more than 150 mg/dL; and 72

75 ically, animals exhibited randomly increased serum glucose concentrations not associated with impaire

76 st 24 hours after surgery was poor, and mean serum glucose concentrations of 150 mg/dL and higher dur

77 e associated with mean 24 hour postoperative serum glucose concentrations of 150 to 250 mg/dL (incide

78 dministered with Zot was sufficient to lower serum glucose concentrations to levels comparable to tho

79 the composite end points, the median initial serum glucose concentrations were 188 (interquartile ran

80 years and after six years by measurement of serum glucose concentrations while the subjects were fas

81 We compared the initial and peak serum glucose concentrations with hemodynamic variables

82 or insulin resistance and found it improved serum glucose concentrations, even without improving ins

83 nsulin application resulted in a decrease in serum glucose concomitant with an increase in serum porc

84 nicians to know when managing intraoperative serum glucose control.

85 Support Services hemoglobin A1c (HbA(c)) and serum glucose data.

86 In vitro ischemia (oxygen/serum/glucose deprivation) led to a progressive accumula

87 se-3 were processed to their active forms in serum-/glucose-deprived myocytes.

88 ts (55.4 +/- 15.3 years; 65.7% women) with a serum glucose determination on the day of surgery, posto

89 Graft rejection was determined by daily serum glucose determinations, and, at selected time poin

90 Correction for serum glucose did not significantly improve the accuracy

91 Low serum glucose, downregulation of glucose transporter-1 a

92 e killed on postburn days 1, 2, 5, and 7 and serum glucose, electrolytes, acute phase reactant protei

93 ight be associated with hepatic dysfunction, serum glucose elevation, inflammation and even severe ne

94 Sur2(-/-) animals had lower fasting and fed serum glucose, exhibited improved glucose tolerance duri

95 Fasting serum glucose fell from 198 mg/dL preoperatively to 94 m

96 of biopsy in 102 patients was normalized by serum glucose ([Glc]) to a standard of 100 mg/dL.

97 age, body mass index (BMI), blood pressure, serum glucose, glycosylated hemoglobin (HbA1c), blood ur

98 ratio TG/HDL-C, or impaired fasting glucose (serum glucose >/=110 mg/dL) to traditional risk factors

99 Hence, poor glycemic control (A1C >/=8% or serum glucose >/=200 mg/dL) appears to be associated wit

100 in day 11 embryos of severely diabetic rats (serum glucose >20 mmol/l).

101 , and glucose control (diabetes medications, serum glucose, HbA(c), mean serum glucose within 24 hour

102 factors such as diabetes medication history, serum glucose, HbA1c, renal function, BMI, and blood pre

103 Fasting serum glucose, IAPP, and CA 19-9 were measured in 130 su

104 ma (PPARgamma) agonists developed to control serum glucose in patients with diabetes.

105 st of the insulin system, ensures sufficient serum glucose in times of fasting.

106 ouse model that correlated with reduction in serum glucose in tumor-bearing mice.

107 tic and hyperleptinemic as indicated by high serum glucose, insulin and leptin levels.

108 or (TFPI) antigen, and thrombin markers; and serum glucose, insulin, and electrolytes.

109 Fasting serum glucose, insulin, and hemoglobin A1C (HgbA1C) were

110 s study examined the relationship of fasting serum glucose, insulin, C-peptide, glycosylated hemoglob

111 piratory quotient (RQ), temperature, fasting serum glucose, insulin, free fatty acids, and ghrelin we

112 Serum glucose, insulin, IL-6, resistin, and OVA-specific

113 oys with subsequent repeated measurements of serum glucose, insulin, lipids, leptin, and calculated h

114 3(-/-) mice did not detect any alteration in serum glucose, insulin, or lipid levels; glucose or insu

115 After 30 d, serum glucose, insulin, triacylglycerol, total, LDL-chol

116 sion analysis, after controlling for gender, serum glucose, intraocular pressure, anterior chamber de

117 value (SUV), with and without correction for serum glucose level (SUV(gluc)); and to evaluate the use

118 Patients were stratified by serum glucose level on day 1 to 7 (low, 0-150 mg/dL; med

119 The group's mean serum glucose level was 6.0 mmol/L at the first visit an

120 p between average SUV or peak SUV and age or serum glucose level was observed.

121 score, systolic blood pressure reading, and serum glucose level was the best triage model for decisi

122 bles (eg, age, sex, baseline weight, fasting serum glucose level), diet variables (eg, carbohydrate c

123 iatrogenic hypoglycemia, particularly at low serum glucose levels (<3 mM).

124 GIK patients had lower serum glucose levels (138+/-4 versus 260+/-6 mg/dL; P<0.

125 adjuvant gemcitabine (n = 107) with elevated serum glucose levels (HgbA1C > 6.5%) exhibited improved

126 Elevated serum glucose levels also correlated with the severity o

127 e, higher baseline body mass indexes, higher serum glucose levels and albuminuria, similar baseline s

128 sgene in wild-type mice resulted in elevated serum glucose levels and decreased ketone levels.

129 Activation of CAR significantly reduces serum glucose levels and improves glucose tolerance and

130 l TG mice displayed significant reduction in serum glucose levels and in hepatocyte glycogen storage

131 TNF-alpha administered to mice decreased serum glucose levels and increased muscle F2,6BP levels;

132 pathy in the absence of long-term effects if serum glucose levels are well monitored and controlled p

133 agic pancreatitis, all recipients maintained serum glucose levels at less than 130 mg/dL without insu

134 Maintaining serum glucose levels between 120 and 180 mg/dL with cont

135 Metformin lowers serum glucose levels by activating 5'-AMP-activated kina

136 Diabetes was confirmed by serum glucose levels exceeding 16 mmol/l during the expe

137 s (RR, 1.8 [CI, 1.1 to 3.0]) or preoperative serum glucose levels exceeding 16.6 mmol/L (RR, 3.7 [CI,

138 emonstrate in vivo by its ability to depress serum glucose levels in a dose-dependent manner.

139 injury was suggested by the observation that serum glucose levels were correlated with tubulointersti

140 Serum glucose levels were decreased in fasted mice and L

141 BLI signals and serum glucose levels were measured daily after transplan

142 Null animals had lower fasting serum glucose levels when compared with wild type contro

143 , systolic and diastolic blood pressure, and serum glucose levels with a requisite increase in the nu

144 oss of white blood cells and fluctuations of serum glucose levels, or patient preference.

145 in, resulting in stunted growth and elevated serum glucose levels, respectively.

146 ly with lowered insulin secretion, increases serum glucose levels, which stimulates de novo lipogenes

147 of the protein with respect to reduction of serum glucose levels.

148 in obese (ob/ob) mice significantly lowered serum glucose levels.

149 nM); PTH(1-34) did not significantly change serum glucose, lipids, body weight, or fat mass.

150 Serum glucose, lipids, insulin, leptin, estradiol, and p

151 otential for use as dietary ingredients with serum glucose lowering activity in humans.

152 ressure <140/90 mm Hg, and untreated fasting serum glucose <100 mg/dL.

153 to 200 mg/dL) with GIK or standard therapy (serum glucose <250 mg/dL) using intermittent subcutaneou

154 e ingestion resulted in lower peak levels of serum glucose (mean difference, 41.0 mg/dL [95% CI, 27.7

155 A commercial laboratory measured serum glucose (non-fasting), albumin, cholesterol, high-

156 te of <20 mmol/L (OR, 2.9; 95% CI, 1.6-5.6), serum glucose of >180 mg/dL (OR, 2.8; 95% CI, 1.6-4.8),

157 not found between ICAM-1 and fasting or 2-h serum glucose or systolic or diastolic blood pressure.

158 d mortality predictability of A1C and random serum glucose over time in a contemporary cohort of 54,7

159 otein (HDL) cholesterol (<0.0001), decreased serum glucose (P < 0.001), increased calorie intake (P <

160 surface adipocyte areas (P < 0.0001), lower serum glucose (P = 0.04), lower serum insulin (P = 0.03)

161 on Comorbidity Index (r = 0.232, p < 0.001), serum glucose (r = 0.172, p < 0.001), BMI (r = 0.133, p

162 es that the use of hypothermia preserves CSF/serum glucose ratio, decreases CSF protein and nitric ox

163 nimum temperature and pH, and higher maximum serum glucose recorded.

164 enge attenuated the rise in the postprandial serum glucose response (P < 0.0001) and resulted in lowe

165 The strength of the serum glucose results after controlling for BMI suggests

166 diabetes, as there were no abnormalities in serum glucose, serum insulin or the ability of insulin t

167 on class, ischemic etiology, statin use, and serum glucose, TFA levels were positively associated wit

168 impaired the ability of adiponectin to lower serum glucose, though other actions of the hormone were

169 Adiponectin lowers serum glucose through suppression of hepatic glucose pro

170 6 in Stockholm, Sweden, with measurements of serum glucose, total cholesterol, triglycerides, apolipo

171 2001, assessed body mass index, heart rate, serum glucose, triglycerides and high-density lipoprotei

172 The mean admission serum glucose value was 141 +/- 36 mg/dL (range, 64-418

173 ine levels can be used to estimate long-term serum glucose values and can be measured in frozen serum

174 lin doses were calculated based on predicted serum glucose values from corrected point-of-care glucom

175 Postoperative serum glucose values were available for 136 patients (79

176 Serum glucose values were elevated in the maternal sampl

177 Preoperative serum glucose values were similar between groups (309+/-

178 Serum glucose was also determined.

179 After 90 days, serum glucose was analyzed to document diabetes; alveola

180 Serum glucose was associated with hypertriglyceridemia w

181 Serum glucose was measured at 6 hr after transplant and

182 At the endpoint, the postprandial rise in serum glucose was reduced at 1 h by 1.3 mmol/l and at 2

183 roughout the study, the postprandial rise in serum glucose was significantly lower during insulin lis

184 Anthropometry and fasting serum glucose were measured, and lower-leg skeletal musc

185 Glycosylated hemoglobin, serum glucose while fasting, serum total cholesterol, hi

186 tes medications, serum glucose, HbA(c), mean serum glucose within 24 hours after surgery).